Research Article

XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications during a Long-Term Follow-Up

Table 3

Clinical characteristics of the study group.

CharacteristicN%Median (Q1; Q3)Range

BCVA change in the combined procedure group, n (%)
Decline1/1010
No change1/1010
Increase8/1090

BCVA change in the solo procedure group, n (%)
Decline12/5920.3
No change13/5922.0
Increase34/5957.6

IOP change, n (%)
Decline49/6476.6
No change5/647.8
Increase10/6415.6
Decline ≥ 20%9/6414.1
Decline < 20%40/6462.5
IOP final level ≤ 15 mmHg31/6448.4
Massage recommendation, n (%)13/7218.0
Needling, n (%)43/6467.2
Number of needling procedures432.00 (1.50; 3.00)1–12
Number of drugs before surgery674.00 (3.00; 5.00)1–5
Time to inclusion of first drug, days5449.50 (20.50; 137.50)0–764
Final number of drugs672.00 (1.00; 4.00)0–4
Complications, n (%)23/6933.3
Reoperations, n (%)17/7123.9

Combined procedure: XEN implantation with phacoemulsification; solo procedure: XEN implantation.